---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-25-000074"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T17:25:47.516395+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Recursion Q1 net loss widens to $202.5M; Sanofi milestone $7M; pipeline refocused

## Summary
- Q1 net loss $202.5M vs $91.4M YoY; revenue $15M (up from $14M).
- Cash & equivalents $509M; projected cash runway into mid-2027; 2025 cash burn ≤$450M.
- Achieved 4th Sanofi milestone, $7M payment; total Sanofi cash inflow $130M to date.
- Deprioritized 3 clinical programs (REC-2282, REC-994, REC-3964) to focus on oncology and rare disease.
- REC-4881 preliminary data: median 43% polyp burden reduction in FAP Phase 1b/2 study.

## SEC filing metadata
- accession: 0001601830-25-000074
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000074/0001601830-25-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000074/rxrx-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-25-000074
- JSON: https://secwatch.observer/filing/0001601830-25-000074.json
- Plain text: https://secwatch.observer/filing/0001601830-25-000074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.